Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Eisai Inc.
Information provided by (Responsible Party):
Northwestern University
ClinicalTrials.gov Identifier:
NCT01372579
First received: June 1, 2011
Last updated: June 30, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2019
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):